A conjugate, its preparation method and use

By conjugating the α-galactosylceramide analog KRN7000 with the glycoantigen TF to form a conjugate, the stability and side effects of traditional glycoprotein vaccines are solved, achieving highly efficient tumor cell recognition and killing effects, which is suitable for the preparation of tumor vaccines.

CN117024494BActive Publication Date: 2026-07-10GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Filing Date
2023-07-28
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

Existing tumor glycoprotein vaccines have problems such as unstable carrier protein coupling sites, potential for autoantibody responses and side effects, and the need for cold chain transportation. The quality control of traditional glycoprotein vaccines is difficult to guarantee.

Method used

An α-galactosylceramide analog (KRN7000) was used as an adjuvant to conjugate with the glycoantigen TF to form a conjugate, which served as a fully synthetic glycoantigen vaccine, enhancing immunogenicity and inducing T cell-mediated humoral immune responses.

Benefits of technology

The conjugate can induce high concentrations of high-affinity IgG antibodies without external adjuvants, specifically recognizing and killing tumor cells, simplifying the preparation process and making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117024494B_ABST
    Figure CN117024494B_ABST
Patent Text Reader

Abstract

The present application relates to a kind of conjugates and its preparation method and application, belong to medical technology field.The present application provides a kind of conjugates, the conjugate includes alpha-galactosylceramide analogue and sugar antigen;It is the compound of general formula (I) or its isomer, pharmaceutically acceptable salt, hydrate or solvate compound.The conjugate has the advantages of clear structure, simple synthesis method, product quality stable and controllable, etc., the tumor sugar vaccine prepared can induce mouse to produce antibody for sugar antigen TF, the antibody serum can specifically recognize and kill tumor cell, and it is expected to become a new generation of antitumor drug.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Conjugate containing alpha-galactosylceramide analogue and carbohydrate antigen as well as preparation method and application of conjugate

    CN111760021A

  • Trehalose derivative and carbohydrate antigen conjugate as well as preparation method and application thereof

    CN111875649A

  • Synthetic tumor vaccine containing alpha-GalCer endogenous adjuvant

    CN114259559A